Thu.May 23, 2024

article thumbnail

At long last, AstraZeneca, Pfizer, J&J, Roche and others have an ally in Biden

Fierce Pharma

Over the last four years, with President Joe Biden milking a popular cause as an opponent of Big Pharma drug pricing, the industry has rarely seen good news coming from the White House. | Over the last four years, with President Joe Biden milking a popular cause as an opponent of Big Pharma's pricing, the industry has rarely seen good news coming from the White House.

Pharma 324
article thumbnail

Is the Healthcare Industry Embracing Risk in Its Contracts?

MedCity News

As the healthcare industry slowly moves toward value-based care, healthcare companies are thinking about taking on risk. During a panel at MedCity News’ INVEST conference, healthcare leaders shared some key ideas about how the industry is embracing risk in its contracts. The post Is the Healthcare Industry Embracing Risk in Its Contracts? appeared first on MedCity News.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

ASCO: Bristol Myers unveils I-O triplet data in melanoma as Iovance touts ‘paradigm-changing’ combo result

Fierce Pharma

Over the years, melanoma has become a popular testing ground for researchers to explore new immuno-oncology approaches. | With prior approvals in melanoma, Bristol Myers Squibb and Iovance are now showcasing early clinical data for their novel combinations in small first-line melanoma trials.

295
295
article thumbnail

Progressing personalised cell therapies in oncology

European Pharmaceutical Review

Last month, CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) was the first BCMA-targeted CAR-T cell therapy to be approved for second-line treatment of multiple myeloma by the US Food and Drug Administration (FDA). In this Q&A, Dr Imran Khan, PhD, Vice President Medical Affairs, Hematology at Johnson & Johnson Innovative Medicine, highlights the current landscape of CAR T therapies such as CARVYKTI and touches on the future direction of the sector.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

J&J faces allegations it used 'fraudulent maneuvers' to avoid compensating talc plaintiffs

Fierce Pharma

As Johnson & Johnson sorts through a mountain of litigation claiming its talcum-based powders caused users to develop cancers, the company has now been slapped with a related but different | Women represented by six law firms who previously filed lawsuits against J&J over talc claims have filed a proposed class action lawsuit in U.S. federal court in New Jersey.

268
268
article thumbnail

Biogen Agrees to Acquire HI-BIO for $1.15 Billion

Pharmaceutical Commerce

The deal features felzartamab, an investigational anti-CD38 monoclonal antibody, whose clinical outcomes have shown potential to tackle various immune-mediated diseases.

105
105

More Trending

article thumbnail

Researchers combine herpes virus with cancer vaccine to treat brain cancer in children

PharmaTimes

High-grade gliomas are rare, malignant tumours which account for up to 12% of all childhood brain tumours

130
130
article thumbnail

Cytokinetics eyes go-it-alone strategy for aficamten

pharmaphorum

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is prepared to go to market on its own.

Leads 102
article thumbnail

Hims & Hers Offers Access to GLP-1s Starting At $199 A Month

MedCity News

Hims & Hers is now providing access to compounded GLP-1s. Patients also receive unlimited medical consultations with a licensed provider. The post Hims & Hers Offers Access to GLP-1s Starting At $199 A Month appeared first on MedCity News.

article thumbnail

Development of novel water-soluble inks for 3D-printed polypills

European Pharmaceutical Review

A paper has reported a multi-material ink-jet 3D printing (MM-IJ3DP)-based method that could enable tailored drug release profiles of personalised pharmaceutical tablets during manufacturing. While biocompatible water-soluble polymers as excipients, have “been recently explored to produce gels [they have not been investigated] as a water-soluble excipient”, according to the paper.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Unlocking Better Health: The Role of Personal Health Literacy in Medicare Advantage Enrollment

MedCity News

The impact of personal health literacy on seniors The post Unlocking Better Health: The Role of Personal Health Literacy in Medicare Advantage Enrollment appeared first on MedCity News.

Patients 106
article thumbnail

AstraZeneca and Nona Biosciences sign agreement for monoclonal antibody

Pharmaceutical Technology

AstraZeneca has entered into a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal antibody.

115
115
article thumbnail

Second fire at Novo Nordisk in a week now under control

pharmaphorum

Novo Nordisk’s second facility fire in a week is under control, although the office in Bagsvaerd affected by the latest blaze isn’t expected to be salvageable.

104
104
article thumbnail

Merck’s MilliporeSigma agrees to acquire Mirus Bio for $600m

Pharmaceutical Technology

Merck KGaA’s MilliporeSigma has entered a definitive agreement for the acquisition of Mirus Bio in a deal totaling $600m (€500m).

104
104
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Merck builds in cell, gene therapies with Mirus Bio deal

pharmaphorum

Merck KGaA has agreed to a $600m deal to buy Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies.

106
106
article thumbnail

Asymchem Takes Ownership of Former Pfizer Manufacturing Facilities

Pharmaceutical Commerce

The CDMO will run the active pharmaceutical ingredient pilot plant in Sandwich, UK, along with development laboratories.

article thumbnail

Chinese firm throws lifeline to Pfizer UK plant workers

pharmaphorum

China’s Asymchem Laboratories has agreed to take over the operation of a Pfizer manufacturing facility in Sandwich, UK, saving dozens of jobs.

article thumbnail

Navigating Opportunities and Challenges in the GLP-1 Drug Gold Rush

MedCity News

GLP-1 agonists are transforming the weight loss market. Experts weighed in on the changes they’re seeing, speaking in a panel discussion during the MedCity News INVEST Conference in Chicago. The post Navigating Opportunities and Challenges in the GLP-1 Drug Gold Rush appeared first on MedCity News.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Biogen bets $1.15bn on immunology drug developer HI-Bio

pharmaphorum

Biogen has expanded its specialty immunology pipeline with an agreement to buy Human Immunology Biosciences (HI-Bio) and its lead drug felzartamab, in trials for a range of diseases including IgA nephropathy (IgAN).

Leads 84
article thumbnail

UK MRC and AstraZeneca partner for translational clinical research

PharmaTimes

The partnership will provide six MRC clinical fellows with industry placement opportunities

Medical 101
article thumbnail

Elite 2024 Data Miner Karin Hayes of OptimizeRx

PM360

Karin Hayes SVP, Analytics Products and Services OptimizeRx Innovation Data Connection to Fuel Patient Centricity Karin Hayes is a transformative leader who combines her strong pharmaceutical background with deep expertise in longitudinal healthcare data and advanced analytics to bring strategic data solutions to pharmaceutical marketing. As the industry navigates advanced analytics and machine learning, Karin stands out as a healthcare leader who turns numbers into insights.

article thumbnail

Challenges and opportunities in synthetic clinical trials

pharmaphorum

What are the pros and cons of synthetic clinical trials? Get insights from podcast guests Web Sun and Tracy Mayne on the latest developments in this cutting-edge field.

59
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Elite 2024 Disrupter Tim Arendt of Consulting Hot Iron Health, a Spectrum Science company

PM360

Tim Arendt Managing Director, Consulting Hot Iron Health, a Spectrum Science company Charging Into New Consulting Models Tim Arendt was once a firefighter. It’s why he’s not afraid to head in first. Tim rejects the status quo and changes how the industry operates. His focus on healthcare brands and their challenges is rooted in a passion for patients and positive patient outcomes.

article thumbnail

Effective Onboarding Strategies for New Medical Sales Reps: Setting the Foundation for Success

Rep-Lite

When bright, enthusiastic new medical sales reps join your team, they’re eager to learn and full of potential. But in reality, they also face a mountain of information about the company, products, and the intricacies of medical sales. An effective onboarding program is the key that unlocks their potential and propels them towards success. Here at Rep-Lite , we’ve witnessed the transformative power of well-designed onboarding firsthand.

article thumbnail

FDA Approves Phase III Trial Protocol for Laekna’s LAE002 Plus LAE001 Combination for the Treatment of Prostate Cancer

PharmExec

Approval for the Phase III protocol of LAE002 Plus LAE001 come as a result of posiive Phase II data, which showed promising benefits for metastatic castration-resistant prostate cancer (mCRPC) patients.

FDA 52
article thumbnail

Magazine: Lula’s progress plan for Brazil: a year on

Pharmaceutical Technology

In this issue: Lula's progress plan for Brazil, tracking opioid lawsuit settlements in the US, the cell & gene therapy landscape in the US, the latest on ESG in pharma, and more.

Pharma 52
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Unlocking the Secrets of High-Performing Sales Teams

Spotio

In a recent webinar hosted by SPOTIO, we delved into the secrets behind high-performing sales teams. Presented by Trey Gibson, CEO/Founder of SPOTIO, the session offered valuable insights from SPOTIO’s annual State of Field Sales study. If you missed it, don’t worry—we’ve summarized the key takeaways to help you transform your sales team’s performance.

Sales 52
article thumbnail

Elite 2024 Disrupter Mike Edwards of Novartis

PM360

Mike Edwards Executive Director, Marketing Strategy Malignant Hematology Novartis Never Settling for Strong, Only Stronger Chronic myeloid leukemia (CML) was a complacent treatment category in need of a disruptor. Enter Mike Edwards, who leads the SCEMBLIX brand team at Novartis. CML has been relatively well-controlled for more than a decade—to the point where some HCPs are so satisfied with their treatment options that they refer to it as the “good cancer.

article thumbnail

CCC to Issue Updates to Market Report on Scholarly Metadata at the Society for Scholarly Publishing Annual Meeting

Copyright Clearance Center

May 23, 2024 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, announces that the newest edition of The State of Scholarly Metadata report, which depicts the complexities and value of scholarly publishing metadata, will be made available at the 2024 Society for Scholarly Publishing (SSP) 46 th Annual Meeting 29-31 May at the Westin Boston Seaport District.

article thumbnail

Elite 2024 Disrupter Alex Sophocles of imre

PM360

Alex Sophocles Vice-President, Experience imre The Benefits of Saying, “What If?” Alex is an integrated marketing strategist with over 13 years of experience leading consumer, healthcare, and medical brands to success. Using human-centered methodologies, he approaches business challenges by collaborating with patients and healthcare professionals to ensure business goals and customer values are aligned.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A